Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
1. RLYB212 program for FNAIT discontinued due to ineffectiveness. 2. Phase 2 trial showed RLYB212 couldn't meet target concentrations. 3. Rallybio shifts focus to RLYB116 and emerging programs. 4. Stock down 40.6% to $0.25 after program discontinuation. 5. Long-term potential remaining in RLYB116 estimated over $6 billion.